Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 european HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 16, Issue 3, 1997, Pages 153-160

  Lundgren, Jens D ^a,k   Phillips, Andrew N ^b   Vella, Stefano ^c   Katlama, Christine ^d   Ledergerber, Bruno ^e   Johnson, Anne M ^f   Reiss, Peter ^g   Gatell, José ^h   Clumeck, Nathan ⁱ   Dietrich, Manfred ^j   Benfield, Thomas L ^a   Nielsen, Jens O ^a   Pedersen, Court ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h H Clinic i Provincial   (Spain)

ⁱ UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^j BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^k HVIDOVRE HOSPITAL   (Denmark)

more..

Author keywords

Antiviral therapy; Epidemiology; Europe; Prophylaxis

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIMYCOBACTERIAL AGENT; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DAPSONE; DIDANOSINE; ETHAMBUTOL; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LAMIVUDINE; MACROLIDE; PENTAMIDINE; RIFABUTIN; RIFAMPICIN; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CANDIDIASIS; COMBINATION CHEMOTHERAPY; EASTERN EUROPE; EUROPE; FEMALE; GEOGRAPHIC DISTRIBUTION; HETEROSEXUALITY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SOUTHERN EUROPE;

EID: 12644313222     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199711010-00003     Document Type: Article

References (23)

1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987;317:185-91.
2. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind, placebo-controlled study. Ann Intern Med 1990;112:727-77.
3. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative study. N Engl J Med 1992;326:437-43.
4. Volberding PA, Lagakos SW, Kock MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with less than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322:941-9.
5. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81.
6. Lundgren JD, Phillips AN, Pedersen C, et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. JAMA 1994;271:1088-92.
7. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and human immunodeficiency virus type 1 disease progression during antiretroviral therapy. Ann Intern Med 1995;122:401-8.
8. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91.
9. US Public Health Service Task Force on Antipneumocystis Prophylaxis in Patients with Human Immunodeficiency Virus Infection. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. J AIDS 1993;6:46-55.
10. Reef SE, Mayer KH. Opportunistic candidal infections in patients infected with human immunodeficiency virus: prevention issues and priorities. Clin Infect Dis 1995;21(suppl 1):S99-S102.
11. Masur H. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium Avium Complex recommendations on prohpylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med 1993;329:898-904.
12. Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbid Mortal Wkly Rep 1992;41:1-19.
13. Lundgren JD, Pedersen C, Clumeck N, et al. Survival differences in European AIDS patients 1979-1989. BMJ 1994;308:1068-1073.
14. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differenees in the use of drug therapy for HIV disease in an urban community. N Engl J Med 1994;330:763-8.
15. Park LP, Graham NMH, Jacobson LP, et al. Factors associated with changes in the use of antiretroviral therapy by a cohort of homosexual men infected with human immunodeficiency virus type 1. Clin infect Dis 1995;21:930-7.
16. Fischl MA. Treatment of HIV infection. In: Sande MA, Volberding PA, eds. The medical management of AIDS. Philadelphia: WB Saunders, 1995:141-60.
17. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
18. Collier AC, Coombs RW, Fischl MA, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993;119:786-93.
19. Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A, the Multicenter AIDS Cohort Study Group. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990;322:161-5.
20. Lundgren JD, Barton SE, Lazzarin A, et al. Factors associated with the occurrence of Pneumocystis carinii pneumonia in 5025 European AIDS patients. Clin Infect Dis 1995;21:106-13.
21. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomised trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332: 693-9.
22. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. Clin Infect Dis 1996; 173:219-25.
23. Nightingale SD, Cameron W, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993;329:829-833.